key: cord-0694102-7hq10f2a
authors: Dror, A. A.; Morozov, N.; Daoud, A.; Namir, Y.; Orly, Y.; Shachar, Y.; Lifshitz, M.; Segal, E.; Fischer, L.; Mizrachi, M.; Eisenbach, N.; Rayan, D.; Gruber, M.; Bashkin, A.; Kaykov, E.; Barhoum, M.; Edelstein, M.; Sela, E.
title: Pre-infection 25-hydroxyvitamin D3 levels and association with severity of COVID-19 illness
date: 2021-06-07
journal: nan
DOI: 10.1101/2021.06.04.21258358
sha: f74fd24065476878d0826c7f27f830726729d1a2
doc_id: 694102
cord_uid: 7hq10f2a

Objective: Studies have demonstrated a potential link between low vitamin D levels and both an increased risk of infection with SARS-CoV-2 and poorer clinical outcomes but have not established temporality. This retrospective study examined if, and to what degree, a relationship exists between pre-infection serum vitamin D levels and disease severity and mortality of SARS-CoV-19. Design and patients: The records of individuals admitted between April 7th, 2020 and February 4th, 2021 to the Galilee Medical Center (GMC) in Nahariya, Israel with positive polymerase chain reaction (PCR) tests for SARS-CoV-2 were searched for vitamin D (VitD) levels measured 14 to 730 days prior to the positive PCR test. Measurements: Patients admitted to GMC with COVID-19 were categorized according to disease severity and VitD level. Association between pre-infection VitD levels and COVID-19 severity was ascertained utilizing a multivariate regression analysis. Results: Of 1176 patients admitted, 253 had VitD levels prior to COVID-19 infection. Compared with mildly or moderately diseased patients, those with severe or critical COVID-19 disease were more likely to have pre-infection vitamin D deficiency of less than 20 ng/mL (OR=14.30, 95%, 4.01-50.9; p < .001); be older (OR=1.039 for each year, 95% CI for OR, 1.017-1.061; p< .01), and have diabetes (OR=2.031, 95% CI for OR, 1.04-3.36; p= 0.038). Vitamin D deficiency was associated with higher rates of mortality (p<0.001) and comorbidities including COPD (p=0.006), diabetes (p=0.026), and hypertension (p =0.016). Conclusions: Among hospitalized COVID-19 patients, pre-infection deficiency of vitamin D was associated with increased disease severity and mortality.

Vitamin D (VitD) is most often recognized for its role in bone health, but low VitD levels have been associated with a range of autoimmune, cardiovascular, and infectious diseases due to its role as an essential immunologic mediator 1 . Experimental laboratory evidence evaluating the impact of VitD on immunological responses has shown inhibitory effects on the production of pro-inflammatory cytokines, including TNF-alpha and IL-6, by various mechanisms, including down-regulating viral-induced NFkB activation 2 .

Vitamin D deficiency (VDD) is a global health problem, and its high prevalence in the Middle East is well established 3 . Epidemiological risk factors for VDD include greater skin pigmentation, low sun exposure, use of skin-covering clothes, and a diet low in fish and dairy products. Studies have previously demonstrated that social habits in specific ethnic groups and a preference to wear long clothing outdoors are independent risk factors for VDD, particularly among women 4 prognoses include geographic location in northern countries, older age, darker skin pigmentation, BAME ethnicity (Black and minority ethnic groups), male sex, obesity, and preexisting conditions such as diabetes and hypertension; these risk factors are also independently associated with VDD 7 .

As with other respiratory infections, a link between VDD and COVID-19 infection is emerging 8, 9 . Low serum 25-hydroxyvitamin levels among hospitalized COVID-19 patients have also been linked with increased disease severity and poorer clinical outcomes 10 . In addition, hospitalized COVID-19 patients have been shown to present lower mean and median levels of VitD than the general population and COVID-19 outpatients 11 . However, serum VitD levels are often measured during hospitalization for COVID-19.

When this is the case, determining the direction and temporality of the association between acute COVID-. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 7, 2021. ; https://doi.org/10.1101/2021.06.04.21258358 doi: medRxiv preprint 19 disease and low VitD serum levels is a challenge. In other words, it is difficult to ascertain a definitive causative effect of baseline VitD level on a clinical presentation during active COVID-19 infection.

To better understand the temporal sequence between low VitD levels and association with severity of acute COVID-19 disease course, we determined whether the severity of disease among patients admitted with acute COVID-19 correlated with their most recent pre-infection VitD serum levels.

This was a retrospective study. Prior to study initiation, ethical approval was granted by the Research Ethics Committee of the Galilee Medical Center 20 -0204 -NHR. Inclusion criteria were adult patients with PCRconfirmed COVID-19 infection admitted to Galilee Medical Center (GMC) between April 7 th , 2020, and February 4 th , 2021. Patients under the age of 18 years old were excluded from this study.

COVID-19 infection was confirmed by two independent positive polymerase chain reaction (PCR) tests.

Clinical data collected during the inpatient hospital stay at Galilee Medical Center included length of hospitalization in days, the severity of illness (critical, severe, moderate, and mild, as determined by the WHO definition of COVID-19 disease severity (WHO/2019-nCoV/clinical/2020.5)), mortality during hospitalization, and comorbidities (COPD, chronic heart failure, chronic ischemic heart disease, chronic renal disease, diabetes, and hypertension). Additional demographic characteristics included age, ethnicity, and BMI (Table 1) .

Disease severity was calculated at the point of highest severity during the patient's inpatient stay; as an example, a patient who arrived at the hospital in mild condition but decompensated to a critical condition during admission would be classified as having had a critical illness. The COVID-19 inpatient group with . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 7, 2021. ; https://doi.org/10.1101/2021.06.04.21258358 doi: medRxiv preprint historical VitD levels admitted to Galilee Medical Center is herein referred to as the "VitD group." The VitD group's 25(OH)D levels were obtained from their respective electronic medical records 14 to 730 days prior to COVID-19 diagnosis. The most recent VitD level from prior to infection with COVID-19 was utilized. Patients with previous VitD measurements had likely been tested either as part of a routine blood workup or following a clinical suspicion for VDD. We did not have access to data regarding whether patients were treated for VDD. Patients' 25(OH)D levels were divided into four universally accepted categories: deficient (below 50 nmol/L or 20 ng/ml), insufficient (50 nmol/L to 75 nmol/L or 20 -29.9 ng/ml), adequate (75-99.75 nmol/L or 30-39.9 ng/ml), and high-normal (above 187.5 nmol/L or 40 ng/mL).

The data utilized for this study is available upon request from the corresponding author.

Continuous variables were presented as the mean ± standard deviation. Comparisons of continuous variables among groups were examined with either the ANOVA, Kruskal Wallis test, independent sample t-test, or Mann-Whitney test. Those tests were chosen according to the number of the compared groups, the sample size of the groups, and the variables' distribution. Ordinal variables were compared among the groups with the Kruskal Wallis test or the Mann-Whitney test and categorical variables using the Pearson's chi-square or the Fisher's exact test (if expectancy<5). With the intention to complete the univariate comparisons of the characteristics between patients, we examined the relationships among several potential predictors of COVID-19 disease severity and the disease severity degree itself. Finally, we examined the correlation between the VitD level and the disease severity degree, adjusted for independent variables which were found to be significant in the univariate analysis or according to theoretical consideration such as age and gender. By calculating the odds ratio (OR) along with 95% confidence intervals (CI), using a multivariate logistic regression model (with the Backward elimination method). We used a statistical significance threshold of P<0.05. The analysis was performed using the IBM SPSS Statistic software, version 27.0.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 7, 2021. Multivariate analysis in individuals with prior VitD levels found that compared with those with mild or moderate COVID19 disease, those with severe or critical disease were14 times more likely to have VitD deficiency <20g/nl (OR=14.30, 95% CI, 4.01-50.9; p-value < .001) ( Table 3 ). Multivariate analysis in individuals with prior VitD levels found that compared with those with mild or moderate COVID19 disease, those with severe or critical disease were14times more likely to have VitD deficiency <20g/nl (OR=14.30, 95% CI, 4.01-50.9; p-value < .001) ( Table 3 ). The variables included in step 1 of this model were age, gender (male), BMI, and comorbidities. The final model represents the last step of the backward elimination process following the adjustment of confounding factors (Table 3) .

A comparison of VitD levels among COVID-19 disease severity categories demonstrated a progressive decrease in levels of VitD as the disease severity increased (Figure 1 ). A significant difference in VitD level was found between mild compared with moderate disease categories (P =0 .001) and moderate compared with severe (P =0.002) (in the mild group, 8.8% had a level less than 20 ng/mL, as well as 58.1% in the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 7, 2021. ; https://doi.org/10.1101/2021.06.04.21258358 doi: medRxiv preprint moderate group, and 86.5% in the severe patients) ( Figure 1 and Table 2 ). No difference between severe and critical individuals with regards to VitD (P =0.405) was observed ( Figure 1 ).

While both age and VitD baseline are independent predictors of increased disease severity, further analysis found a significant correlation between VDD when stratifying patients into three age groups (<50, 50-65, ≥65) ( Figure 2 ). The strongest correlation between lower VitD level and COVID-19 disease severity was seen in ≥65 years old patients (r =-0.717; p-value < 0.001). In patients under 50 years of age, COVID-19 severity was still correlated with VitD deficiency but to a lesser extent (r =-0.566; p-value < 0.001).

In this retrospective single-institution study, we demonstrate a correlation between low vitamin D levels prior to COVID-19 infection and increased COVID-19 disease severity and mortality during hospitalization.

The vital role of VitD during the COVID-19 pandemic has been highlighted beyond its well-known benefit for bone and muscle health as a regulatory component of the innate and adaptive immune response during viral infections. Other hallmarks of COVID-19 disease have been linked with VitD status, including the cytokine storm that portends acute respiratory distress syndrome. Several studies demonstrated the association of VDD in a patient's history with increased risk for positive COVID-19 test results 12, 13 . Existing research has suggested a correlation between low 25-hydroxyvitamin D levels upon admission as a predictor of poorer COVID-19 disease outcomes 14,15 . However, a low level of serum VitD measured during the acute COVID-19 infection may reflect a consequence of chronic inflammation rather than an underlying cause. By using the most recent historical VitD levels, the obtained vitamin D value in our study assuredly preceded COVID-19 infection.

We found that lower VitD levels were associated with greater disease severity and mortality. While 48.1% of VitD deficient <20 ng/mL patients had severe disease courses, less than 10% of patients with VitD levels . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 7, 2021. ; https://doi.org/10.1101/2021.06.04.21258358 doi: medRxiv preprint ≥20 ng/mL had severe courses. While the mortality of patients who had VitD levels ≥20 ng/mL was at 5% or lower, the mortality of VitD deficient patients <20 ng/mL was much higher, at 25.6%. Older age is associated with both VitD deficiency and poorer COVID-19 outcomes. To adjust for this variable, we performed a multivariate analysis which adjusted for age as a confounder, demonstrating that pre-infection VDD increased the risk of severe COVID-19 disease, independent of age. Reduced VitD levels in younger COVID-19 inpatients may suggest an increased hospitalization risk due to COVID-19 illness in this group with severely low VitD while older patients remain at increased risk of hospitalization for COVID-19, even at higher levels of the VDD range.

The higher ratio of female-to-male patients in the VitD group (56.9% females) compared to the non-VitD group (50.4% females) may be explained by the higher risk of osteoporosis, and subsequently vitamin D testing, in women. Status as a postmenopausal woman is a known risk factor for the development of VDD, thus increasing the likelihood of a woman having had VitD testing 16 . Because VitD and calcium supplementation have been shown to reduce the risk of fractures in the elderly, there is the possibility that patients with previously low VitD results have taken supplementation, which significantly increases serum VitD levels. Furthermore, previous studies have established that Israel, a sunny country, has high levels of VitD insufficiency or deficiency; this may predispose individuals or their providers to consider supplementation, particularly for women 17 .

Despite the significant propensity for VDD among Arab ethnicities, our data showed no effect of ethnicity on disease severity and mortality (Tables 1 and 2 ). This evidence implies that baseline serum VitD level is more significant to COVID-19 disease course than ethnicity, at least in our cohort. While the high percentage of VDD in Arabs (64.3% of patients with VitD <20 ng/mL) compared with others was consistent with previous research demonstrating high rates of VDD in Arabs, including in Arab-American and Arab-European populations, this may be the result of a higher frequency of VitD testing in this population 18, 19 . A proposed explanation for this finding is a higher level of skin pigmentation that decreases dermal vitamin D synthesis 20 . It is not unlikely that the skin's increased pigmentation, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. There are several important limitations of the study. First, vitamin D deficiency can be a part of a wide range of chronic health conditions or behavioral factors that simultaneously increase COVID-19 disease severity and mortality risks. As an example, COPD, while associated with VDD in our study, is a known risk factor for poorer COVID-19 outcomes. It should be clearly stated that a patient's historically low VitD levels do not cause COVID-19 but rather may increase the likelihood of SARS-COV-2 infection and morbidity and mortality under various clinical settings [23] [24] [25] . Moreover, VitD correction in the community setting preceding the infection will not necessarily improve the future COVID-19 disease course of an affected individual. Patients' supplementation history was not obtained or analyzed as part of this research. The use of historical results from community health providers may be influenced by prior VDD correction therapy given due to low serum levels, the effect of which is difficult to fully deduce.

However, our cohort's strong correlation between prior VDD and COVID-19 disease outcome implies that most patients remain with low VitD levels when contracting COVID-19 infection. Third, despite our findings, it must be acknowledged recent study in India found no association between VDD and increased mortality and morbidity in hospitalized patients 26 . In this prospective study in which patients' VitD levels were measured during hospitalization, the patients had a median age of 54, lower than our cohort's median age of 63.6; as mentioned, older age is associated with increased mortality due to COVID-19.

Additional confounders that possibly contribute to COVID-19 outcome differences between published cohorts stem from the genetic heterogenicity of different populations 21 . A panoply of studies highlights . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 7, 2021. ; https://doi.org/10.1101/2021.06.04.21258358 doi: medRxiv preprint the role of host genetics in susceptibility for COVID-19 disease via polymorphism of different key alleles such as ACE, TMPRSS2, Vitamin D binding protein, and other protein-coding genes which participating in the human innate immune system 27-29 . Our results add to the existing literature suggesting a potential protective effect of adequate VitD levels in patients with active COVID-19 infection. While our findings have identified an association between preinfection VDD and COVID-19 severity, these results do not necessarily imply that VitD treatment will impact COVID-19 outcomes, and we should remain cautious about overestimating the potential benefit of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 7, 2021. ; https://doi.org/10.1101/2021.06.04.21258358 doi: medRxiv preprint It should be emphasized that VitD represents only one piece of the complex puzzle that is COVID-19 in addition to underlying comorbidities, genetic predispositions, dietary habits, and geographic factors.

Despite the numerous studies related to VitD and COVID-19, to date, there is no evidence supporting the administration of supplementary vitamin D for the treatment of active COVID-19 infection.

From the early stages of the COVID-19 pandemic, establishing vitamin D deficiency as a risk factor was the aim of many investigators. It was subject to much debate in the general public and multiple medical journals 35 . Our study contributes to a continually evolving body of evidence that suggests a patient's history of VDD is a predictive risk factor associated with poorer COVID-19 clinical disease course and mortality.

The use of historical results obtained before the COVID-19 pandemic as part of a public health survey enabled us to suggest VDD contributes to the causal pathway of COVID-19 mortality risk and disease severity. Our study warrants further studies investigating if and when VitD supplementation among VitD deficient individuals in the community impacts the outcome of an eventual COVID-19 episode.

1.

Charoenngam N, Holick MF. Immunologic effects of vitamin d on human health and disease.

Nutrients. 2020;12 (7):1-28. doi:10.3390/nu12072097 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 7, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 7, 2021. ; https://doi.org/10.1101/2021.06.04.21258358 doi: medRxiv preprint Figure 2 . Correlation between VDD and COVID-19 disease severity stratified by three different group of age (<50, 50-65, ≥65). The severity of illness (critical, severe, moderate, and mild, as determined by the WHO definition of COVID-19 disease severity (WHO/2019-nCoV/clinical/2020.5))

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 7, 2021. ; https://doi.org/10.1101/2021.06.04.21258358 doi: medRxiv preprint

Vitamin D and immune function

Vitamin D in the Middle East and North Africa

Vitamin D status in Jordan: dress style and gender discrepancies

Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials

Perspective: Vitamin D deficiency and COVID-19 severity -plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis

Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results

Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study

Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers

Vitamin D deficiency as risk factor for severe COVID-19: a convergence of two pandemics. medRxiv

Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results

Association of Vitamin D Levels, Race/Ethnicity, and Clinical Characteristics with COVID-19 Test Results

Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity

Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19

Vitamin D status among postmenopausal osteoporotic women: a hospital based cross-sectional study from Northern Sri Lanka

Vitamin D insufficiency in a sunny environment: A demographic and seasonal analysis

Effect of race and genetics on vitamin D metabolism, bone and vascular health

Covid-19: Black people and other minorities are hardest hit in US

Association of Vitamin D Levels, Race/Ethnicity, and Clinical Characteristics with COVID-19 Test Results

Association of vitamin D status and other clinical characteristics with COVID-19 test results

Association of Vitamin D Status With Hospital Morbidity and Mortality in Adult Hospitalized Patients With COVID-19

Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19

Genetic polymorphisms, vitamin D binding protein and vitamin D deficiency in COVID-19

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor